RecruitingEarly Phase 1NCT06002477

Attentional Mechanisms in SCD

Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline

Sponsor

Vanderbilt University Medical Center

Enrollment

80 participants

Start Date

Jun 6, 2025

Study Type

INTERVENTIONAL

Conditions

Subjective Cognitive Decline

Summary

This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.

Eligibility

Min Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mecamylamine Challenge and Placebo Comparator Challenge for people with subjective cognitive decline. The study is currently recruiting participants at 1 location. People eligible for this study include aged 55 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.